Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
- 15 May 2012
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (10), 3492-3497
- https://doi.org/10.1016/j.bmcl.2012.03.085
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerTrends in Endocrinology & Metabolism, 2010
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)Journal of Medicinal Chemistry, 2010
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerClinical Cancer Research, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate CancerCancer Research, 2008
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate CancerClinical Cancer Research, 2005
- Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBritish Journal of Cancer, 2004